On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiaries Work to Secure New Deals for DehydraTECH in Various Industries

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is finding success through its ability to form subsidiaries specializing in the use of its patented drug-delivery platform, DehydraTECH. A recent article discussing the company reads, “DehydraTECH is a drug-delivery platform patented for cannabidiol and all other nonpsychoactive cannabinoids, as well as THC (tetrahydrocannabinol) and psychoactive cannabinoids. The technology … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiaries Work to Secure New Deals for DehydraTECH in Various Industries”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Execute Clinical Studies on Oral Forms of Nicotine Delivery Using DehydraTECH

LXRP’s DehydraTECH research funded by a partner that will provide $1 million, with an option for millions more LXRP subsidiary Lexaria Nicotine LLC recently entered a definitive investment agreement to receive R&D funding in exchange for equity and licensing rights In exchange, partner received minority equity interest in the subsidiary Lexaria Bioscience Corp. (CSE: LXX) … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Execute Clinical Studies on Oral Forms of Nicotine Delivery Using DehydraTECH”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Creates Unique Opportunity in Global Cannabis Industry

Big corporations are investing in the cannabis industry Major tobacco company provides financing for LXRP LXRP boasts revenue streams within the nicotine industry and opportunity in other sectors Lexaria is a unique company doing business on its own terms The cannabis industry is experiencing impressive growth thanks to both legal and social changes worldwide, and … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Creates Unique Opportunity in Global Cannabis Industry”

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiary Secures Key R&D Funding for Oral Nicotine Delivery Using DehydraTECH Technology

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) wholly owned subsidiary, Lexaria Nicotine LLC, recently struck a deal with a large tobacco partner, securing significant R&D financing for the company’s DehydraTECH absorption platform (http://cnw.fm/12hJT).  A recent article discussing the company reads, “Through the agreement, the partner also has the option to provide up to $11 million in additional … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiary Secures Key R&D Funding for Oral Nicotine Delivery Using DehydraTECH Technology”

CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advanced Technology Attracts Outside Investment

Related Editorial Revolutionary innovations and advancements within the cannabis industry are drawing significant investment from big corporations. Technology currently in development will make it easier to consume active ingredients in cannabis. Advances have attracted investment for the technology’s use in tobacco as well as cannabis. These improvements could move consumers to healthier forms of consumption … Continue reading “CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advanced Technology Attracts Outside Investment”

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Seeks to Improve Lives through Revolutionary Nicotine Delivery Method

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has joined forces with one of the world’s largest tobacco companies to fund the research and development of Lexaria’s patented DehydraTECHÔ technology to potentially commercialize a form of oral nicotine delivery. An article discussing the company reads, “Lexaria’s goal … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Seeks to Improve Lives through Revolutionary Nicotine Delivery Method”

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Receives New R&D Funding for Oral Nicotine Delivery Technology

LXRP subsidiary Lexaria Nicotine LLC enters definitive investment agreement with large tobacco company to receive R&D funding in exchange for licensing and equity Partner has provided initial $1 million – with an option for up to $11 million more – for research on DehydraTECH’s oral forms of nicotine delivery through a series of private financings … Continue reading “Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Receives New R&D Funding for Oral Nicotine Delivery Technology”

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery

Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected for cannabidiol and all other nonpsychoactive cannabinoids. The company also currently has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An article discussing the company reads, “Lexaria Bioscience has 10 patents … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Acquires a $12 Million Investor

Lexaria Nicotine LLC partners with one of the world’s largest tobacco companies Opportunity to change nicotine delivery and improve the lives of millions Retains ownership of DehydraTECH while licensing the technology out to multiple industries Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has partnered with … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Acquires a $12 Million Investor”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives $1 Million from New Partnership with Altria to Fund DehydraTECH R&D

LXRP’s subsidiary, Lexaria Nicotine LLC, enters definitive investment agreement with Altria Ventures Inc.; Altria to fund R&D, receive license rights and equity Altria will fund research on LXRP’s DehydraTECH oral nicotine products, pay sales royalties and may fund up to $12 million more through a series of private financings LXRP has not sold or optioned … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives $1 Million from New Partnership with Altria to Fund DehydraTECH R&D”

Contact us: 303.498.7722